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Vaping Linked with Severe Lung Illnesses 
Background 
“Vaping” refers to the use of an electronic device (e-cigarette, vape, vape-pen, etc.) with a heating 
element that, when activated, vaporizes a liquid so that the user of the device can inhale the vapour. 
The liquid, made for this purpose and commonly called an “e-liquid,” contains solvents, additives, 
water, flavourings and diverse active ingredients, usually liquid nicotine or cannabinoids, such as 
THC and CBD,* suspended in oils. The vapours, when inhaled by the person who vapes, produces 
psychoactive effects. While nicotine and cannabinoids are the most common psychoactive drugs 
consumed through vaping (Jones, Hill, Pardini, & Meier, 2016; Tucker et al., 2019), recent evidence 
shows that e-cigarettes can also be used as a way to deliver other non-medical psychotropic 
substances, such as methamphetamine and heroin (Breitbarth, Morgan, & Jones, 2018; Krakowiak, 
Poklis, & Peace, 2019).  
Earlier studies suggested that vaping nicotine is less harmful to the lungs and respiratory system 
than cigarette smoking (National Academies of Sciences, Engineering, and Medicine, 2018), and 
consequently vaping has emerged as a common method of inhaling nicotine and cannabinoids. 
According to the 2017 Canadian Tobacco, Alcohol and Drugs Survey, 15% of Canadians in the 
general population (aged 15 years and older) reported using an e-cigarette in their life, which 
represents a significant increase from the 13% reported in 2015 (Statistics Canada, 2017).  
Even more concerning is the popularity of vaping among youth and this is a trend that appears to be 
steadily growing. According to the most recent data obtained by the Youth Tobacco and Vaping 
Survey of the International Tobacco Control Policy Evaluation Project, 37% of Canadians aged 16 to 
19 years old reported lifetime use of a nicotine e-cigarette in 2018, which represents a significant 
increase from the 29.3% reported in 2017 (Hammond et al., 2019). Vaping has also become a 
common way of inhaling cannabis among Canadians, with 29% of cannabis-using individuals (aged 
15 years and older) indicating that vaping is their preferred method for cannabis use (Statistics 
Canada, 2017).  
Current Developments 
While it is believed by consumers that vaping nicotine is a healthier alternative to conventional 
cigarettes, it has recently been demonstrated that vaping is linked with severe lung and pulmonary 
illnesses (Layden et al., 2019). The U.S. Centers for Disease Control and Prevention (CDC) has 
identified 1,888 confirmed and highly probable cases of pulmonary illnesses resulting from vaping in 
the United States and 37 patients have died from the illnesses (Centers for Disease Control and 
Prevention, 2019).† The CDC analysis showed that 79% of the cases have occurred in adults aged 
                                                 
* Tetrahydrocannabinol (THC) is the main psychoactive cannabinoid in cannabis. Cannabidiol (CBD) is the main non-psychoactive 
cannabinoid in cannabis  
† The CDC statistics are updated weekly. The figures used in this report are up to date as of October 31, 2019. 
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under 35 years old; 70% of the cases were male. To date, Health Canada has reported two 
confirmed cases in the province of Quebec of a pulmonary illness that has resulted from vaping; two 
probable cases have been identified in New Brunswick and one probable case in British Columbia 
(Health Canada, 2019).  
The reported symptoms include respiratory dysfunctions (shortness of breath, cough, pleuritic chest 
pain) and gastrointestinal disorders (diarrhea, nausea, vomiting). A high percentage of patients also 
showed leukocytosis (high white blood cell count), indicating a strong inflammatory response by the 
immune system (Layden et al., 2019). Other details of the U.S. cases include: 
 All reported cases have used an e-cigarette containing either THC or nicotine or a combination of 
both within the 90 days before developing symptoms (Layden et al., 2019).  
 Most of the cases of emerging lung and respiratory disorders (over 75%) have been linked to 
vaping products containing THC from cannabis extracts (Layden et al., 2019). 
 The THC vape cartridges used in the cases were mostly, but not exclusively, purchased from the 
illicit market. 
To deal with the emergence of lung illnesses associated with vaping in Canada, the Public Health 
Agency of Canada and the Council of Chief Medical Officers of Health have organized a federal, 
provincial and territorial task group on severe pulmonary illness related to vaping. The task group 
aims to develop a uniform approach to identifying and reporting cases, and is working collaboratively 
to develop technical documents (e.g., a Canadian case definition), data collection tools and 
information-sharing processes (Health Canada, 2019).  
Beside Health Canada’s response to the outbreak, the Government of Canada has established a 
strong regulatory framework for vaping products. Vaping products that do not contain cannabis are 
regulated by the Tobacco and Vaping Products Act and the Canada Consumer Product Safety Act. 
Additional regulatory measures, such as strictly restricting vaping product advertising, packaging and 
flavours will be applied to further reduce and prevent uptake of nicotine vaping products by youth. 
Vaping products containing cannabis are regulated separately under the Cannabis Act. The purpose 
of these acts is to protect public health and public safety with regards to the use of any sort of vaping 
products. 
What Is Accounting for Lung and Pulmonary Illnesses in 
People Who Vape? 
Although no substance or product has yet been clearly identified as the cause for the illnesses, the 
CDC reports that chemical exposure might play a key role. At first, the CDC and FDA were pointing at 
vitamin E acetate for several cases. According to the CDC, laboratories have identified high levels of 
vitamin E acetate in many of the vaping product samples they have analyzed. Other toxicants such 
as flavouring substances and solvents in e-liquids are also being investigated.  
Vitamin E Acetate in E-liquids 
Vitamin E acetate (also called tocopheryl acetate) is a form of vitamin E usually found in skin care 
products or dietary supplements. When applied topically or taken orally over a short-term period, 
vitamin E acetate is harmless. However, long-term oral exposure to high doses of vitamin E acetate 
can increase the risk of heart failure (Lonn et al., 2005) and all-cause mortality (Miller et al., 2005). 
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There is a common misconception among people who use cannabinoid oil that the thickness of the 
oil indicates its quality. To exploit this misconception, illicit market suppliers have used vitamin E 
acetate as a thickening agent in cannabinoid-infused oils to mimic this characteristic of what users 
think is high-quality pure oil. In past years, vitamin E acetate was found in small quantities in vape 
oils (less than 20%), but with the increased popularity of vaping, illicit market suppliers have started 
to add larger amount of vitamin E acetate in their oil products (more than 50%). The effects of 
inhaling high doses of vitamin E are currently unknown and more studies are needed. However, the 
FDA has warned that when inhaled vitamin E could lead to lipoid pneumonia. 
E-flavours in E-liquids 
There are more than 7,500 e-liquid flavours available (Zhu et al., 2014), and some of them have the 
potential to be harmful when heated and inhaled (National Academies of Sciences, Engineering, and 
Medicine, 2018). For instance, saccharides, used to sweetened e-liquid flavours, can produce 
respiratory irritants such as furans and aldehydes when heated (Soussy et al., 2016; Tierney, Karpinski, 
Brown, Luo, & Pankow, 2016). Diacetyl, acetylpropionyl and acetoin are chemicals that are added to 
e-liquids (Allen et al., 2016) to produce various candy flavours. When heated and inhaled, these 
flavouring substances have been associated with adverse respiratory health consequences including 
chronic cough, bronchitis, asthma and bronchiolitis obliterans, a severe and irreversible lung illness 
that can lead to pulmonary scarring and obstruction (Kreiss et al., 2002; National Academies of 
Sciences, Engineering, and Medicine, 2018). Finally, pulegone, a substance found in high levels in 
mint and menthol flavoured e-liquids, has possible carcinogenic properties, and preclinical studies 
showed that oral administration of pulegone in rodents can cause hepatic carcinomas, pulmonary 
metaplasia and other neoplasms (Jabba & Jordt, 2019). To date, there is little information available 
about the health effects of flavouring agents in e-liquids and more studies are needed to determine 
if they are safe to inhale. 
Other Potential Toxins in E-liquids 
Beside vitamin E acetate, e-liquids contain other chemicals known to have potentially deleterious 
effects on health. For example, the most popular solvents found in e-liquids to dissolve nicotine or 
cannabinoids are vegetable glycerin and propylene glycol. The heating process that vaporizes the 
e-liquid in an e-cigarette is sufficient to induce a thermal decomposition of both vegetable glycerin 
and propylene glycol into carbonyl compounds, such as formaldehyde, acetaldehyde, acrolein, 
acetone and propanal, all substances known to have toxic properties and to induce mouth, throat 
and lung irritation (Goniewicz et al., 2014; Kosmider et al., 2014). For example, formaldehyde is a 
strong respiratory irritant and is classified by the International Agency for Research on Cancer as a 
human carcinogen (Jensen, Luo, Pankow, Strongin, & Peyton, 2015). Acrolein can damage the lung 
lining, irritate the nasal cavity and contribute to cardiovascular disease (Park & Taniguchi, 2008). 
Acetone is a mucous membrane irritant and inhalation can also lead to hepatotoxic effects (Buron, 
Hacquemand, Pourie, & Brand, 2009).  
The release of toxicants into the lungs from e-cigarettes can vary depending of the model of vaping 
device, the material from which a device is made (e.g., plastic, metal, glass) and the heating-coil. For 
instance, using a vaping device with a higher battery output that will increase the heat generated by 
the heating coil can produce and release more chemicals and toxicants (Geiss, Bianchi, & Barrero-
Moreno, 2016; Kosmider et al., 2014). However, it is important to note that the amount of chemicals 
and contaminants in aerosols from e-cigarettes is found at lower levels than in tobacco or cannabis 
cigarette smoke (National Academies of Sciences, Engineering, and Medicine, 2018). 
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Key Considerations 
Rigorous testing of vaping products for toxic substances is essential to ensuring the health and 
safety of people who vape. Studies are needed to evaluate the presence of potentially toxic and 
hazardous compounds in e-liquids and the vapours generated from them by vaping devices. While 
cannabinoid e-liquids in newly legalized products that will soon be appearing on the market will be 
strictly tested and regulated, concerns about the health effects of vaping remain. Due to the lack of 
epidemiological studies and large clinical trials, the short- and long-term health effects of vaping and 
vaping products are unknown and more studies are required to determine their health impacts.  
While additional scientific information is gathered, the following suggestions are made to protect the 
health of those are considering vaping or who already vape: 
 For health reasons, people should not vape. 
 People who do vape should avoid doing so until there is more conclusive evidence of a specific 
agent causing the illnesses. 
 People who vape should not buy any e-cigarettes or vaping products from the illicit market. 
 People who vape should closely monitor themselves and seek medical attention for any 
symptoms of cough, shortness of breath, chest pain, nausea, diarrhea or vomiting. 
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